Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology

Biogen executives said the company is seeking to return to growth by diversifying beyond its historical neurology concentration, advancing a broader late-stage pipeline, and managing expenses. The comments signal a strategic focus on pipeline expansion and cost discipline, but the excerpt provides no financial targets, trial data, or guidance changes.